

TIBO

Figure 1. Molecular representation of (+)-(S)-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-*jk*][1,4]benzodiazepine-2(1*H*)-thione with the numbering system.




Figure 2. Stereoscopic ORTEP diagrams of molecules A (a) and B (b).

include AZT,^{3a-d} 3'-azido-2',3'-dideoxyuridine,^{3d} 3'-azido-2',3'-dideoxy-5-ethyluridine,^{3d} 2',3'-dideoxycytidine,⁴ 2',3'-dideoxyadenosine,⁵ 3'-deoxythymidine,⁶ 3'-fluoro-3'-deoxythymidine,⁷ 2'-fluoro-2',3'-dideoxyarabinosyladenine,⁸ and 2'-fluoro-2',3'-dideoxyarabinosylhypoxanthine.⁸

X-ray diffraction analysis of R82913 reveals that there are two independent molecules (designated A and B) in the asymmetric unit of the crystal, having rather different conformations (Figure 2, parts a and b).^{9,13} They mutually interact by forming reciprocal

(3) (a) Gurskaya, G. V.; Tsapkina, E. N.; Skaptsova, N. V.; Kraevskii, A. A.; Lindeman, S. V.; Struchkov, Y. T. *Dokl. Akad. Nauk SSSR* **1986**, *291*, 854-859. (b) Birnbaum, G. I.; Giziewicz, J.; Gabe, E. J.; Lin, T.-S.; Prusoff, W. H. *Can. J. Chem.* **1987**, *65*, 2135-2139. (c) Camerman, N.; Mastroiolo, D.; Camerman, A. *Proc. Natl. Acad. Sci. U.S.A.* **1987**, *84*, 8239-8242. (d) Van Roey, P.; Salerno, J. M.; Duax, W. L.; Chu, C. K.; Ahn, M. K.; Schinazi, R. F. *J. Am. Chem. Soc.* **1988**, *110*, 2277-2282.

(4) Birnbaum, G. I.; Lin, T.-S.; Prusoff, W. H. *Biochem. Biophys. Res. Commun.* **1988**, *151*, 608-614.

(5) Chu, C. K.; Nhadit, V. S.; Doboszewski, B.; Gu, Z. P.; Kosugi, Y.; Pullaiah, K. C.; Van Roey, P. *J. Org. Chem.* **1989**, *54*, 2217-2225.

(6) Van Roey, P.; Salerno, J. M.; Chu, C. K.; Schinazi, R. F. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 3929-3933.

(7) Camerman, N.; Mastroiolo, D.; Camerman, A. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *87*, 3534-3537.

(8) Liaw, Y.-C.; Gao, Y.-G.; Marquez, V. E.; Wang, A. H.-J., in preparation.




Figure 3. A superposition of R82913 (conformer A; filled bonds) to deoxyadenosine 5'-monophosphate (open bonds; ref 21) with adenine in the syn conformation.

hydrogen bonds between N1 and S (N1_A-S_B, 3.249 (6) Å; N1_B-S_A, 3.310 (6) Å). The benzimidazole rings stack over each other, with the thione group lying over the fused tricyclic ring system near its center (location close to C12) on one side and the chlorine atom lying under the imidazole ring on the other side. The methylbutenyl groups from molecules A and B are packed together in the lattice using only van der Waals forces (Figure 1S, supplementary material), resulting in large temperature factors for those side chains.

In both molecules the benzimidazole ring (including N1, C2, N3, C8-C13, Cl, and S atoms) is mostly planar. Molecule A has its seven-membered diazepine ring in the *TS* conformation.¹⁴ The methylbutenyl group is above the mean plane, with C15 at the axial position and the H16 pointing away from the molecule. In contrast, the diazepine ring of molecule B is in the *TC/BS* conformation¹⁴ with C15 in an equatorial position. The conformational changes can be described mainly by the torsion angles along two bonds of the seven-membered ring: C5-N6 (-83.4° in A and 46.2° in B) and N6-C7 (68.8° in A and -93.8° in B). The torsion angle along the C15-C16 bond remains similar in the two mol-

(9) Crystals of R82913 with an elongated rod shape were grown from a mixture of a methanol-water 10 mM solution by slow evaporation at room temperature.¹⁰ Two independent datasets were collected, one (crystal size 0.2 × 0.2 × 0.4 mm) on a Rigaku AFC-5R rotating anode X-ray diffractometer at 25 °C using the ω -scan mode with Cu K α radiation (to $2\theta = 120^\circ$; 0.89-Å resolution) and the other (crystal size 0.2 × 0.2 × 0.6 mm) on an Enraf-Nonius CAD4 diffractometer at -110 °C using variable scan with Mo K α radiation (to $2\theta = 60^\circ$; 0.71-Å resolution). After Lp and absorption correction, there were 2476 (out of 2656) and 3198 (out of 4952) independent reflections observed at the 4.0 $\sigma(F)$ level above the background, and they were used in the refinement. Their crystal structures are designated as RT and LT structures, respectively. The LT dataset has 81% observed reflections to 0.9-Å resolution and 48% between 0.9- and 0.71-Å resolution. They were in the monoclinic space group C2 with $a = 31.384$ (6) Å, $b = 10.747$ (2) Å, $c = 9.975$ (2) Å, and $\beta = 92.19$ (2)° for RT and $a = 30.938$ (6) Å, $b = 10.653$ (3) Å, $c = 9.880$ (5) Å, and $\beta = 93.22$ (3)° for LT. The RT structure was solved first by direct methods using the program SHELXS-86.¹¹ It was refined by full-matrix least squares using the NRCVAX package.¹² There are two independent R82913 molecules in the asymmetric unit. All 42 non-hydrogen atoms were refined anisotropically. Forty hydrogen atoms were also included in the refinement with fixed positions and isotropic temperature factors. The final *R* factors are 4.8% (RT) and 5.4% (LT), which are slightly higher than that from an exceptionally well refined structure. This may be due to the less ordered methylbutenyl side chains in the molecules discussed in the text. The LT structure was refined with better temperature factors, and their atomic coordinates (listed in Table 1S, supplementary material) are used for discussions in this paper.

(10) The compound was purchased from Pharmatech International, Inc., NJ, as a free base (purity >99%). We have not been able to crystallize the hydrochloride salt of the compound.

(11) Sheldrick, G. M. In *Crystallographic Computing 3*; Sheldrick, G. M., Kruger, C., Goddard, R., Eds.; Clarendon Press: Oxford, 1985; pp 175-189.

(12) Gabe, E. J.; Lee, F. L.; Le Page, Y. In *Crystallographic Computing 3*; Sheldrick, G. M., Kruger, C., Goddard, R., Eds.; Clarendon Press: Oxford, 1985; pp 167-174.

(13) A search of the Cambridge Data Base revealed no crystal structure of any derivative belonging to the TIBO family. It appears that this is the first crystal structure of its kind.

(14) The diazepine conformation is defined as described by Boessenkool and Boeyens (Boessenkool, I. K.; Boeyens, J. A. *J. Cryst. Mol. Struct.* **1980**, *10*, 11-18). Molecule A has the puckering amplitudes of $q_2 = 0.15$ Å and $q_3 = 0.53$ Å and pseudorotation $\phi_2 = 150.7^\circ$ and $\phi_3 = 165.8^\circ$. Molecule B has $q_2 = 0.80$ Å and $q_3 = 0.36$ Å and $\phi_2 = 29.0^\circ$ and $\phi_3 = 145.2^\circ$.

ecules (124.9° in A and 123.9° in B) despite the different dispositions of the methylbutenyl group. The conformation of this type of diazepine ring (fused to a benzo ring) that is seen in molecule B occurred more frequently (in 111 out of 122 molecular fragments) according to our search of the current Cambridge Data Base.

The differences in the conformation have some effects on the geometry associated with the diazepine ring and the methylbutenyl side chain. The most prominent features are the bond angles at the N3 and C13 atoms. The endocyclic angles of C4-N3-C12 and C7-C13-C12 in A (127.6 (5)° and 123.9 (6)°) are significantly greater than those of B (124.1 (5)° and 119.5 (6)°). In addition, some bond lengths associated with the C5 and N6 atoms and the methylbutenyl group for A/B molecules have variations greater than 5 esd's. The differences associated with the methylbutenyl group are likely due to their large temperature factors described earlier. Other differences may be related to the conformation around nitrogen N6. Both N6 atoms have sp³ character as reflected in the distance of N6 from the plane of C5, C7, and C15 (0.360 (6) Å for A and 0.368 (7) Å for B). Notice that N6 retains the same chirality (*S*) in both conformers and its lone-pair electrons point away from the center in molecule A, but toward the center in molecule B.

The observation of two distinct conformations in the crystal suggests that at least two conformers are in equilibrium in solution. A series of one-dimensional NMR spectra at different temperatures showed that two molecular species coexist in equilibrium on the NMR time scale up to 20 °C.¹⁵ At -40 °C, these two species are clearly resolved into two populations (90%:10%). Interconversion of the two conformers involves flipping of the methylbutenyl side chain from one side of the aromatic ring plane to the other side, with modest energy barriers. The difference in total energies associated with these two conformers is 1.3 kcal/mol on the basis of the calculation using MOPAC¹⁷ with PM3 force field parameters.¹⁸ Conformation A has lower energy, and this suggests that it is the major species in solution. These two conformers may be considered as atropisomers, reminiscent of an ansamycin antibiotic, streptovaricin C,¹⁹ also an inhibitor for RTase.

The mode of action of R82913 appears to be quite different from that of the dideoxynucleosides.^{2,20} Whether the conformations seen in the present crystal structure or the flexibility associated with the diazepine ring is relevant to its biological function as an inhibitor for the RTase of HIV-1 remains to be conclusively answered by solving the structure of the complex between RTase and the inhibitor. However, it is interesting to note that the molecule contains a conjugated ring system not unlike a purine ring. A superposition of molecule A with deoxyadenosine 5'-monophosphate²¹ (with adenine in the syn conformation) reveals the overall similarity between them (Figure 3). It is conceivable that the nucleotide triphosphate binding site in RTase has a cavity

that can accommodate this inhibitor and bind it extremely tightly. It has been previously noted that nucleoside analogues containing an ethylene moiety such as a cyclopentene ring are excellent inhibitors for enzymes in the nucleoside synthesis pathway²² and for HIV viruses.²

Acknowledgment. This work was supported by grants from the NSF and NIH (A.H.-J.W.). We thank Dr. J. A. Katzenellenbogen for useful comments. Y.-C.L. acknowledges support from the Institute of Molecular Biology, Taiwan (ROC).

Supplementary Material Available: A table of the fractional atomic coordinates of the two independent molecules of R82913 of the LT form and a figure showing the packing interactions (3 pages). Ordering information is given on any current masthead page.

(22) Moyer, J. D.; Malinowski, N. M.; Treanor, S. P.; Marquez, V. E. *Cancer Res.* **1986**, *46*, 3325-3329.

Iron Chelate Mediated Proteolysis: Protein Structure Dependence

Tariq M. Rana and Claude F. Meares*

*Department of Chemistry, University of California
Davis, California 95616*

Received August 14, 1990

Cleavage of DNA or RNA by metal chelates is an important new approach to characterizing important structural features of nucleic acids and their complexes in solution.¹ Naturally occurring proteases and selective peptide cleaving agents are useful for dissecting protein structure and function, but more choices are desirable.² Artificial proteolytic reagents which are directed by *proximity* rather than by residue type represent a new approach which could be employed for sequence analysis, functional analysis of structural domains, or determining the spatial arrangement of subunits within a supramolecular structure. They could also be incorporated into new, targeted therapeutic agents.

Recently, there has been considerable interest in the cleavage of proteins by metal ions or chelates bound at particular sites.^{3,4} In our laboratories, site-specific cleavage of proteins is achieved by introducing a metal-binding site at one position in a polypeptide chain. Recently, we found that an iron chelate attached to cysteine-34 of the protein bovine serum albumin hydrolyzed the protein backbone at two sites—between Ala-150 and Pro-151, and between Ser-190 and Ser-191—without excessive decomposition of amino acid side chains.^{4a}

This approach could permit mapping a site of interest by determining which individual peptide bonds are adjacent to it. However, because no crystal structure is available for bovine serum albumin, no detailed information concerning the steric require-

(15) NMR spectra were recorded on a GE GN-500 500-MHz spectrometer. The sample was 20 mM R82913 in deuterated methanol. The temperature range was from -60 °C to 40 °C. The smaller population (10%) starts to become evident at 0 °C for some resonances. The population ratio remains unchanged throughout the temperature range. However, the crystallization process selects out the 1:1 ratio of the two conformers to form the crystal lattice, thereby shifting the equilibrium in solution. This phenomenon is quite common in the crystallization of many biological macromolecules. For example, the minor species Z-DNA, instead of the abundant B-DNA, crystallized from the low-salt solution of d(CGCGCG) readily.¹⁶

(16) Wang, A. H.-J.; Quigley, G. J.; Kolpak, F. J.; Crawford, J. L.; van Boom, J. H.; van der Marel, G. A.; Rich, A. *Nature (London)* **1979**, *282*, 680-686.

(17) Stewart, J. J. P. 1987, MOPAC Version 5.0, QCPE No. 455.

(18) Stewart, J. J. P. *J. Comput. Chem.* **1989**, *10*, 209-215.

(19) Rinehart, K. L., Jr.; Knoll, W. M. J.; Kakinuma, K.; Antosz, F. J.; Paul, I. C.; Wang, A. H.-J.; Reusser, F.; Li, L. H.; Kreuger, W. C. *J. Am. Chem. Soc.* **1975**, *97*, 196-197.

(20) Another non-nucleoside compound with significant anti-HIV activity has recently been synthesized: Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Faanes, R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L. *Science* **1990**, *250*, 1411-1413.

(21) Reddy, B. S.; Viswamitra, M. A. *Acta Crystallogr.* **1975**, *B31*, 19-26.

(1) (a) Moser, H. A.; Dervan, P. B. *Science (Washington, D.C.)* **1987**, *238*, 645-650. (b) Chen, C. B.; Sigman, D. S. *Science (Washington, D.C.)* **1987**, *237*, 1197-1201. (c) Tullius, T. D.; Dombroski, B. A. *Proc. Natl. Acad. Sci. U.S.A.* **1986**, *83*, 5469-5473. (d) Cech, T. R.; Latham, J. A. *Science (Washington, D.C.)* **1989**, *245*, 276-282. (e) Mei, H. Y.; Barton, J. K. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 1339-1343.

(2) (a) Stark, G. *Adv. Protein Chem.* **1970**, *24*, 261. (b) Spande, T. F.; Witcop, B.; Degani, Y.; Patchornik, A. *Adv. Protein Chem.* **1970**, *24*, 98. (3) (a) Rush, J. D.; Koppenol, W. H. *J. Biol. Chem.* **1986**, *261*, 6730-6733; *J. Am. Chem. Soc.* **1988**, *110*, 4957-4963. (b) Brodie, B. B.; Axelrod, J.; Shore, P. A.; Udenfriend, S. *J. Biol. Chem.* **1954**, *208*, 741-750. (c) Kim, K.; Rhee, S. G.; Stadtman, E. R. *J. Biol. Chem.* **1985**, *260*, 15394-15397. (d) Tabor, S.; Richardson, C. C. *J. Biol. Chem.* **1987**, *262*, 15330-15333. (e) Chiou, S.-H. *J. Biochem.* **1983**, *94*, 1259-1267.

(4) (a) Rana, T. M.; Meares, C. F. *J. Am. Chem. Soc.* **1990**, *112*, 2457-2458. (b) Schepartz, A.; Cuenoud, B. *J. Am. Chem. Soc.* **1990**, *112*, 3247-3249. (c) Hoyer, D.; Cho, H.; Schultz, P. G. *J. Am. Chem. Soc.* **1990**, *112*, 3249-3250.